Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors
Recent studies demonstrated a significantly increased frequency of epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) patients with malignant pleural effusions (MPEs). The purpose of this study is to investigate the effect of first-line and second-line EGFR-...
Saved in:
| Main Authors: | Zhen Zheng, Deyao Xie, Huafang Su, Baochai Lin, Lihao Zhao, Xia Deng, Hanbin Chen, Shaoran Fei, Xiance Jin, Congying Xie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-05-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317706211 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors
by: Nikhil Vojjala, et al.
Published: (2025-01-01) -
Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01) -
Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01) -
Rational computational Design of new-Generation EGFR tyrosine kinase (EGFR-TK) inhibitors
by: Chandraprakash Gond, et al.
Published: (2025-05-01) -
MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis
by: Defeng Hu, et al.
Published: (2025-04-01)